Agios Stock Poised To Break Out On $905 Million Brain Cancer Deal

Agios agreed Tuesday to sell its 15% royalty in a brain cancer drug for $905 million upfront. Agios stock broke out at the open.

Related Keywords

Brian Goff ,Agios Pharmaceuticals ,Drug Administration ,Royalty Pharma ,Chief Executive Brian Goff ,